Information includes: definition of epidemic, abuse, how Rx abuse became an epidemic, national stats on emergency room visits, overdoses, ... who are the supplies, end users... misusers by population, cost to our society & economy, ....
Initial progress on the journey toward an open source potential drug-drug int...Richard Boyce, PhD
Presentation given at the 33rd VistA Community Meeting - George Mason University focusing on progress towards and open source potential drug interaction knowledge base
Why is the orphan drug area receiving increasing attention? In this presentation you will find the primary reasons explained.
Over the next weeks, Black Swan Consulting will summarise information on this class of drug products. Please also see http://black-swan-consulting.com/what-is-cooking/Orphan-drugs.
The orphan drug area is relatively new but fast growing. Over the next weeks, Black Swan Consulting will summarise information on this class of drug products. Please also see http://black-swan-consulting.com/what-is-cooking/Orphan-drugs.
Initial progress on the journey toward an open source potential drug-drug int...Richard Boyce, PhD
Presentation given at the 33rd VistA Community Meeting - George Mason University focusing on progress towards and open source potential drug interaction knowledge base
Why is the orphan drug area receiving increasing attention? In this presentation you will find the primary reasons explained.
Over the next weeks, Black Swan Consulting will summarise information on this class of drug products. Please also see http://black-swan-consulting.com/what-is-cooking/Orphan-drugs.
The orphan drug area is relatively new but fast growing. Over the next weeks, Black Swan Consulting will summarise information on this class of drug products. Please also see http://black-swan-consulting.com/what-is-cooking/Orphan-drugs.
Over 30 years after the Orphan Drug Act was passed, orphan drugs continue to be a lucrative market for pharma companies. Although orphan diseases affect small populations, these treatments address a high unmet need and also benefit from commercially attractive pricing structures and additional regulatory benefits.
Full graphic: http://www.isrreports.com/free-resources/5408/
Availability of essential medicines in Hungary (2017)Arete-Zoe, LLC
This report analyzes availability of essential medicines as defined in the World Health Organization (WHO) Essential List Medicines (Report of the WHO Expert Committee) in Hungary. The WHO list of essential medicines contains most effective and safe medicines needed to meet the most important needs in health systems and is frequently used by countries to create their own national lists. Without these drugs, some conditions will not be able to receive optimal therapy. Availability gap represents serious public health concern. Expert Committee of the World Health Organization selects Essential Medicines Lists in accordance with approved procedures. The Committee evaluates the scientific evidence on the basis of the comparative effectiveness, safety and cost-effectiveness of the medicines.
Mastering Regulatory Approval in New Orphan Drug MarketsLewis Lau
Presented at DIA 2015 Annual Meeting. A symposum titled "A Global Update on Orphan Drug" chaired by Mr Noriaki Murao
http://www.diaglobal.org/en-US/Flagship-Meetings/DIA-Annual-Meeting/Meeting-Program/Find-Sessions-and-Presentations/Event-Details.aspx?productID=3803687&eventType=Symposium&title=A%20Global%20Update%20on%20Orphan%20Drugs
This symposium addresses the current status and forthcoming activities related to orphan drugs in North America, EU and Japan. Orphan drug development is considered essential in these regions, and the various provisions to accelerate the development of orphan drugs have been implemented. However, some challenges still remain for the companies and the agencies wishing to pursue development and approval of orphan drugs in these regions.
Changing times ask for solid relationships.
Times are changing. A renewed interest from big pharma in the rare disease landscape
has awakened due to large-scale patent expirations, competition from generics &
biosimilars, anemic pipelines, escalating clinical trial costs and a global health-care
reform. This means that the traditional blockbuster model has become less viable while
the revenue-generating potential of orphan drugs has shown to be huge with a greater
return on investment than non-orphan drugs. According to EvaluatePharma, the orphan
drugs sales will grow at an annual rate of 11% and constitute 19% of the total share of
prescription drugs by 2020, totalling 176 billion dollars.
The rare disease landscape is very complex due to the large amount of stakeholders
involved. Despite their different interests they have one goal in common: getting an
orphan drug approval that will help save or improve lives. But there are many challenges
on the road to orphan drug designation:
• Complex and changing national and regional regulations
• Clinical trial design and finding & keeping patients
• The lack of a central database designed specifically to list patient registries, which
asks for close stakeholder engagement
• Partnering and establishing financing for future development
• Establishing a foundation for price that is balanced and sustainable
• Achieving an efficient and timely access to market with equal access for patients
around the world
• Achieving timely and correct diagnosis to enable higher quality of life and more time
and information for developers
More information: http://www.orphandrugssummit.com/
Healthcare providers are increasingly breaking the secure supply chain and endangering patients. Learn about counterfeit drugs and most recent incidents involving providers.
Also learn about how you can be a part of the solution by working with the Partnership for Safe Medicines.
Tim Mackey, Assistant Professor, University of California, San Diego - Department of Anesthesiology, speaks about the effect counterfeit Avastin has had on efforts to protect the American public from counterfeit medications.
Counterfeit drugs: what a doctor should knowMark Davison
Short lecture to medical students on risks, prevalence and detection of fake medicines and protection of patient safety. Essential training for new doctors and pharmacists.
Global orphan drug market future outlook 2020KuicK Research
"Global Orphan Drug Market Future Outlook 2020" report highlights:
Global Orphan Drug Market Overview
Global Orphan Drug Market Segment Analysis
FDA & EMA Regulation for Clinical Trials Orphan Designated Drugs
Orphan Drug Designation Criteria & Reimbursement Policy by Region
Comprehensive Insight on Global Orphan Drugs Clinical Pipeline & Patent Analysis by Company, Country, Indication & Phase
Global Orphan Drugs Clinical Pipeline: 697 Drugs
Majority Orphan Drugs in Phase-II Trials: 249 Drugs
Marketed Orphan Drugs: 274 Drugs
The World Health Organization Could Update Cannabis Legalization SoonCannabis News
The WHO could rule on marijuana as soon as next month, read this https://cannabis.net/blog/news/the-world-health-organization-is-reviewing-current-cannabis-laws?
This lecture discusses health policy related to curbing abuse of controlled substances - like narcotics. This article discusses several steps Utah has made to decrease the number of opiate-related deaths.
Over 30 years after the Orphan Drug Act was passed, orphan drugs continue to be a lucrative market for pharma companies. Although orphan diseases affect small populations, these treatments address a high unmet need and also benefit from commercially attractive pricing structures and additional regulatory benefits.
Full graphic: http://www.isrreports.com/free-resources/5408/
Availability of essential medicines in Hungary (2017)Arete-Zoe, LLC
This report analyzes availability of essential medicines as defined in the World Health Organization (WHO) Essential List Medicines (Report of the WHO Expert Committee) in Hungary. The WHO list of essential medicines contains most effective and safe medicines needed to meet the most important needs in health systems and is frequently used by countries to create their own national lists. Without these drugs, some conditions will not be able to receive optimal therapy. Availability gap represents serious public health concern. Expert Committee of the World Health Organization selects Essential Medicines Lists in accordance with approved procedures. The Committee evaluates the scientific evidence on the basis of the comparative effectiveness, safety and cost-effectiveness of the medicines.
Mastering Regulatory Approval in New Orphan Drug MarketsLewis Lau
Presented at DIA 2015 Annual Meeting. A symposum titled "A Global Update on Orphan Drug" chaired by Mr Noriaki Murao
http://www.diaglobal.org/en-US/Flagship-Meetings/DIA-Annual-Meeting/Meeting-Program/Find-Sessions-and-Presentations/Event-Details.aspx?productID=3803687&eventType=Symposium&title=A%20Global%20Update%20on%20Orphan%20Drugs
This symposium addresses the current status and forthcoming activities related to orphan drugs in North America, EU and Japan. Orphan drug development is considered essential in these regions, and the various provisions to accelerate the development of orphan drugs have been implemented. However, some challenges still remain for the companies and the agencies wishing to pursue development and approval of orphan drugs in these regions.
Changing times ask for solid relationships.
Times are changing. A renewed interest from big pharma in the rare disease landscape
has awakened due to large-scale patent expirations, competition from generics &
biosimilars, anemic pipelines, escalating clinical trial costs and a global health-care
reform. This means that the traditional blockbuster model has become less viable while
the revenue-generating potential of orphan drugs has shown to be huge with a greater
return on investment than non-orphan drugs. According to EvaluatePharma, the orphan
drugs sales will grow at an annual rate of 11% and constitute 19% of the total share of
prescription drugs by 2020, totalling 176 billion dollars.
The rare disease landscape is very complex due to the large amount of stakeholders
involved. Despite their different interests they have one goal in common: getting an
orphan drug approval that will help save or improve lives. But there are many challenges
on the road to orphan drug designation:
• Complex and changing national and regional regulations
• Clinical trial design and finding & keeping patients
• The lack of a central database designed specifically to list patient registries, which
asks for close stakeholder engagement
• Partnering and establishing financing for future development
• Establishing a foundation for price that is balanced and sustainable
• Achieving an efficient and timely access to market with equal access for patients
around the world
• Achieving timely and correct diagnosis to enable higher quality of life and more time
and information for developers
More information: http://www.orphandrugssummit.com/
Healthcare providers are increasingly breaking the secure supply chain and endangering patients. Learn about counterfeit drugs and most recent incidents involving providers.
Also learn about how you can be a part of the solution by working with the Partnership for Safe Medicines.
Tim Mackey, Assistant Professor, University of California, San Diego - Department of Anesthesiology, speaks about the effect counterfeit Avastin has had on efforts to protect the American public from counterfeit medications.
Counterfeit drugs: what a doctor should knowMark Davison
Short lecture to medical students on risks, prevalence and detection of fake medicines and protection of patient safety. Essential training for new doctors and pharmacists.
Global orphan drug market future outlook 2020KuicK Research
"Global Orphan Drug Market Future Outlook 2020" report highlights:
Global Orphan Drug Market Overview
Global Orphan Drug Market Segment Analysis
FDA & EMA Regulation for Clinical Trials Orphan Designated Drugs
Orphan Drug Designation Criteria & Reimbursement Policy by Region
Comprehensive Insight on Global Orphan Drugs Clinical Pipeline & Patent Analysis by Company, Country, Indication & Phase
Global Orphan Drugs Clinical Pipeline: 697 Drugs
Majority Orphan Drugs in Phase-II Trials: 249 Drugs
Marketed Orphan Drugs: 274 Drugs
The World Health Organization Could Update Cannabis Legalization SoonCannabis News
The WHO could rule on marijuana as soon as next month, read this https://cannabis.net/blog/news/the-world-health-organization-is-reviewing-current-cannabis-laws?
This lecture discusses health policy related to curbing abuse of controlled substances - like narcotics. This article discusses several steps Utah has made to decrease the number of opiate-related deaths.
Treatment Programs HARPS Program (Helping At-Risk Pregnant Women Succeed) - C...ErikaAGoyer
NATIONAL PERINATAL ASSOCIATION CONFERENCE 2014 - Treatment Programs HARPS Program (Helping At-Risk Pregnant Women Succeed)
- Chris Cooper, MSN, NNP-CB, APRN and Dawn Forbes, MD
Dr. Tom Frieden, Director of the Centers for Disease Control and Prevention, keynote presentation at the National Rx Drug Abuse & Heroin Summit on March 30, 2016.
Securing the Global Pharmaceutical Supply Chain against the Threat of Counter...Yasmin AbdelAziz
In 2012, counterfeit versions of the cancer drug
Avastin were found in 19 American treatment
centers. The impostor drug lacked the active
ingredient, rendering it virtually useless for
treatment purposes.
MEDICAL ETHICS AND CONFLICT OF INTEREST IN SCIENTIFIC MEDICINEhome
SUMMARY
The Office of Technology Assessment (OTA) was perhaps the US government's last honest agency that critically reviewed the state of the nation's health care system. The purpose of the OTA was to provide Congress with objective and authoritative analysis of complex scientific and technical issues. In its final critical report, the OTA concluded: “There are no mechanisms in place to limit dissemination of technologies, regardless of their clinical value.”
Shortly after the OTA released a report that exposed how entrenched financial interests manipulate health care practice in the United States, Congress disbanded the OTA.
Chapter 3Public Health Data and Communications.docxwalterl4
Chapter 3
Public Health Data and Communications
Learning Objectives
Identify six basic types of public health data
Explain the meaning, use, and limitations of the infant mortality rate and life expectancy measurements
Explain the meanings and uses of HALEs and DALYs
Identify criteria for evaluating the quality of information presented on a website
Explain ways that perceptions affect how people interpret information
Learning Objectives
Explain the roles of probabilities, utilities, and the timing of events in combining public health data
Explain the basic principles for the construction of decision trees and their uses
Explain how attitudes, such as risk-taking attitudes, may affect decision making
Identify three different approaches to clinical decision making and their advantages and disadvantages
Vignette 1
You read that the rate of use of cocaine among teenagers has fallen by 50% in the last decade.
You wonder where that information might come from.
Vignette 2
You hear that life expectancy in the United States is now approximately 80 years.
You wonder what that implies about how long you will live and what that means for your grandmother, who is 82 and in good health.
Vignette 3
You hear on the news the gruesome description of a shark attack on a young boy from another state and decide to keep your son away from the beach.
While playing at a friend’s house, your son nearly drowns after falling into the backyard pool.
You ask why so many people think that drowning in a backyard pool is unusual when it is far more common than shark attacks.
Vignette 4
“Balancing the harms and benefits is essential to making decisions,” your clinician says.
The treatment you are considering has an 80% chance of working, but there is also a 20% chance of side effects.
“What do I need to consider when balancing the harms and the benefits?” you ask.
Vignette 5
You are faced with a decision to have a medical procedure.
One physician tells you there’s no other choice and you must undergo the procedure, another tells you about the harms and benefits and advises you to go ahead and the third lays out the options and tells you it’s your decision.
Why are there such different approaches to making decisions these days?
Questions-to-Ask (1)
What is the scope of health communications?
Where does public health data come from?
How is public health information compiled to measure the health of a population?
How can we evaluate the quality of the presentation of health information?
What factors affect how we perceive public health information?
Questions-to-Ask (2)
What type of information needs to be combined to make health decisions?
What other data needs to be included in decision making?
How do we utilize information to make health decisions?
How can we use health information to make healthcare decisions?
Table 3-1 The 6 Ss of Quantitative Sources of Public Health Data (1/3)Type
ExamplesUsesAdvantages/
DisadvantagesSingle case or small seriesC.
Over 350 million people worldwide are suffering from rare diseases. Which is why it is necessary to understand the rare disease landscape to date.
Drug development is challenging at the best of times, and made even harder within the realm of rare diseases. Overall, the largest number of drugs has targeted indications within the therapeutic areas of oncology and infectious disease (ID), with malaria being an area of high interest with both therapeutic and preventive interventions.
View this slideshare to get the most accurate and timely intelligence about rare diseases drug development.
In this detailed 20-page report, containing numerous comparative graphs, you will discover:
- The top 25 Rare Diseases by total drugs in development to date
- Current Rare Disease drug development landscape
- Top 15 originators of drugs in development for Rare Diseases (includes non-rare disease drug counts and % of portfolio dedicated to Rare Diseases)
- Therapeutic area distribution of rare diseases and drugs in development
- The top 5 Rare Diseases by drug count per therapeutic area (TA)
- Rare Infectious Diseases with 10 or more drugs in development
- The top 15 originators developing drugs for Rare Infectious Diseases
- Rare cancers with 10 or more drugs in development
- The top 15 originators developing drugs for rare cancers
- Non-ID, non-cancer Rare Diseases with 20 or more drugs in development
- The top 15 originators developing drugs for non-ID, non-cancer Rare Diseases
The Opioid Epidemic: An Important Auditor UpdatePYA, P.C.
PYA Tampa Office Managing Principal Angie Caldwell and Consulting Senior Manager Sarah Bowman addressed “The Opioid Epidemic: An Important Auditor Update” in their presentation. They:
Provided an overview of the scope of the opioid crisis, emerging trends in opioid abuse, and recent regulatory activity.
Analyzed key internal control risk areas to prevent drug diversion.
Reviewed specific examples of monitoring for fraud and abuse related to the opioid epidemic.
The Skeeterhawk Experiment 2013 Slide Presentation (Prescription Drug Misuse)Skeeterhawk
The Skeeterhawk Experiment was organized in March 2013 to help end the scourge of prescription drug misuse through the testing of innovative prevention, treatment, and overdose rescue strategies in real-life communities, beginning in Northeast Florida. Utilizing data gathered from a multitude of reliable sources, The Skeeterhawk Experiment believes it is possible for every community to devise targeted, data-driven strategies to tackle its unique set of prescription drug misuse problems. This is the organization's Northeast Florida community presentation for 2013.
Similar to 2012 How did Rx abuse become a National Epidemic in the US (20)
Pro-Marijuana advocates continue to promote propaganda that marijuana is safe & harmless for individuals and our society. Facts, research, statistics ... the reality of using & legalizing marijuana.
Honest Reviews of Tim Han LMA Course Program.pptxtimhan337
Personal development courses are widely available today, with each one promising life-changing outcomes. Tim Han’s Life Mastery Achievers (LMA) Course has drawn a lot of interest. In addition to offering my frank assessment of Success Insider’s LMA Course, this piece examines the course’s effects via a variety of Tim Han LMA course reviews and Success Insider comments.
Embracing GenAI - A Strategic ImperativePeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
Model Attribute Check Company Auto PropertyCeline George
In Odoo, the multi-company feature allows you to manage multiple companies within a single Odoo database instance. Each company can have its own configurations while still sharing common resources such as products, customers, and suppliers.
A Strategic Approach: GenAI in EducationPeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
Instructions for Submissions thorugh G- Classroom.pptxJheel Barad
This presentation provides a briefing on how to upload submissions and documents in Google Classroom. It was prepared as part of an orientation for new Sainik School in-service teacher trainees. As a training officer, my goal is to ensure that you are comfortable and proficient with this essential tool for managing assignments and fostering student engagement.
Introduction to AI for Nonprofits with Tapp NetworkTechSoup
Dive into the world of AI! Experts Jon Hill and Tareq Monaur will guide you through AI's role in enhancing nonprofit websites and basic marketing strategies, making it easy to understand and apply.
Palestine last event orientationfvgnh .pptxRaedMohamed3
An EFL lesson about the current events in Palestine. It is intended to be for intermediate students who wish to increase their listening skills through a short lesson in power point.
How to Make a Field invisible in Odoo 17Celine George
It is possible to hide or invisible some fields in odoo. Commonly using “invisible” attribute in the field definition to invisible the fields. This slide will show how to make a field invisible in odoo 17.
Biological screening of herbal drugs: Introduction and Need for
Phyto-Pharmacological Screening, New Strategies for evaluating
Natural Products, In vitro evaluation techniques for Antioxidants, Antimicrobial and Anticancer drugs. In vivo evaluation techniques
for Anti-inflammatory, Antiulcer, Anticancer, Wound healing, Antidiabetic, Hepatoprotective, Cardio protective, Diuretics and
Antifertility, Toxicity studies as per OECD guidelines
Acetabularia Information For Class 9 .docxvaibhavrinwa19
Acetabularia acetabulum is a single-celled green alga that in its vegetative state is morphologically differentiated into a basal rhizoid and an axially elongated stalk, which bears whorls of branching hairs. The single diploid nucleus resides in the rhizoid.
2. An epidemic is the occurrence of
more cases of disease than would
normally be expected in a specific
place or group of people over a
given period of time.
http://www.cdc.gov/excite/classroom/intro_epi.htm
http://www.cdc.gov/mmwr/preview/mmwrhtml/su6004a5.htm?s_cid=su6004a5_w 2
4. Rx Drug Abuse includes:
OR
OR
Taking someone else’s
prescription for
self-medication
Taking a Rx medication in
a way other than intended
Taking medication to get high
http://www.drugabuse.gov/publications/drugfacts/prescription-over-counter-medications 4
6. 100 people die from drug
overdoses every day in the
United States.
CDC. Vital Signs: Overdoses of Prescription Opioid Pain Relievers—United States, 1999-2008.
MMWR 2011; 60: 1-6
http://www.cdc.gov/HomeandRecreationalSafety/rxbrief/states.html 6
8. 0
1
2
3
4
5
6
7
8
9
10
'70 '72 '74 '76 '78 '80 '82 '84 '86 '88 '90 '92 '94 '96 '98 '00 '02 '04 '06
Deathrateper100,000
Heroin
Cocaine
Rx Medication
History of Drug Overdoses
http://www.cdc.gov/HomeandRecreationalSafety/pdf/poison-issue-brief.pdF
National Vital Statistics System, http://wonder.cdc.gov
Eight-Fold Deaths from
Drug Overdoses
1970-2007
8
9. Drug Overdose Death Rates by State, 2007
http://www.cdc.gov/HomeandRecreationalSafety/pdf/poison-issue-
brief.pdf 9
10. http://www.cdc.gov/nchs/data/databriefs/db81.htm
• During the past three decades, the number of drug poisoning deaths increased
sixfold from about 6,100 in 1980 to 36,450 in 2008
• In 2008, poisoning became the leading cause of injury death in the United States
and nearly 9 out of 10 poisoning deaths are caused by drugs.
Poisoning is now the leading cause of death
from injuries in the U.S. and nearly 9 out of
10 poisoning deaths are caused by drugs.
10
11. Emergency Department Visits Involving Illicit
Drugs or Non-Medical Use of Pharmaceuticals,
2004-2009
http://www.oas.samhsa.gov/2k10/DAWN034/EDHighlights.h
tm
11
12. Deaths
Treatment Admission
Emergency Room
Abuse/Misuse
Non-medical use
2008 Statistics: Opioid Pain Relievers deaths
and Related Consequences of Misuse
12
(14,800 people)
(148,000 people)
(473,600 people)
(1,924,000 people)
(12,210,000 people)
2008, Total number of Drug Overdoses was 36,450 of this
number 20,444 were due to Rx abuse and 73% of Rx Deaths
or 14,800 were due to opioid pain relievers (OPR).
http://www.cdc.gov/injury/about/focus-rx.html
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6043a4.htm#tab1
http://www.cdc.gov/nchs/data/databriefs/db81.htm
14. 14
Opioid refers to Narcotic drugs or pain pills
which are DEA controlled substances.
15. 26.7%
15.4%
7.7%
3.5%
4.0%
4.7%
20.2%
2.7%
3.2%
7.4%
4.5%
0.0% 5.0% 10.0% 15.0% 20.0% 25.0% 30.0%
General Practitioners/Family Medicine
Internal Medicine
Dentists
Nurse Practitioners
Physicians Assistants
Emergency Medicine
Other
Physical Med & Rehab
Anesthesiologists
Orthopedist
Unspec.
15SDI, Vector One: National, 2009. Extracted June 2010.
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM217510.pdf
Top 10 Prescribing Specialties
immediate-release opioids, 2009
16. http://www.drugabuse.gov/sites/default/files/rrprescription.pdf
Source of Rx Narcotics
Among Those Who Used in the
Past-Year, 12th Grade
1.10%
11.00%
18.80%
19.50%
32.50%
37.80%
59.10%
Internet
Other
Took from friend/relative
Brough from dealer/stranger
Presription
Bought from friend/relative
Given by friend/relative
Categories are not mutually exclusive
16
19. *Includes pain relievers, tranquilizers, stimulants, and sedatives
Note: The specific drug refers to the drug
that was used for the first time in the past
year, regardless of whether it was the first
drug ever used or not.
New Users in the Past Year of Specific Illicit
Drugs among Persons Aged 12 or Older, 2010
http://www.samhsa.gov/data/NSDUH/2k10NSDUH/2k10Results.htm 19
20. + Difference between this estimate and the 2010 estimate is statistically significant at the .05 level.
Past Month Nonmedical Use of Types of Psychotherapeutic Drugs
among Persons Aged 12 or Older: 2002-2010
http://oas.samhsa.gov/NSDUH/2k10NSDUH/2k10Results.htm#2.16
Past Month Nonmedical Use of Types of
Psychotherapeutic Drugs among
Persons Aged 12 or Older, 2002- 2010
20
21. Sales
Deaths
Treatment
Rates of opioid pain
reliever (OPR)
overdose death, OPR
treatment
admissions, and
kilograms of OPR
sold --- United
States, 1999--2010
21http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6043a4.htm
22. Death Rate
Opioid Sales
Drug overdose death rate in 2008 and rate of
kilograms (kg) of opioid pain relievers (OPR) sold
in 2010 — United States
22http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6043a4.htm
23. From the innocent unborn & infants to the
vulnerable elderly our nation has succumb to
the marketing ploy of drug companies
encouraging the public to utilize Rx drugs for
every minor pain and/or slight feeling of
anxiety.
Sadly, this ploy is working all too well….
23
Nonmedical use of Rx Drugs are Destroying
Families in the United States
24. Patrick, S. W. et al. JAMA
doi:10.1001/jama.2012.3951
Weighted National Estimates of the
Rates of NAS per 1000 Hospital Births
per Year
NAS indicates neonatal abstinence syndrome.
24
27. Current Substance Use Among Pregnant Women
Aged 15-44, by Age, 2008-2009 Combined
http://oas.samhsa.gov/2k9/135/PregWoSubUse.cfm
http://oas.samhsa.gov/2k9/135/PregWoSubUse.htm
27
28. In 2010, 2 million people
reported using prescription
painkillers nonmedically for
the first time within the last
year—nearly 5,500 a day.
First time Users
http://oas.samhsa.gov/NSDUH/2k10NSDUH/2k10Results.htm#2.16 28
31. Full-time college students
who used Adderall®
non-
medically in the past year
were and almost FIVE
times more likely to use
OxyContin®
non-medically
(44.9 vs. 8.6 %).
31http://www.oas.samhsa.gov/2k9/adderall/adderall.htm
College Campus
32. National Institutes of
Health surveys show that
in 2010, the most current
year available, 2.4
million people ages 50-
59 said they had abused
prescription or illegal
drugs within the past
month — almost three
times as many people as
reported that behavior in
2002.
Baby Boomers
http://www.drugabuse.gov/news-events/nida-notes/2010/12/drug-abuse-highest-level-
in-nearly-decade
32
33. At least one in four older adults use
psychoactive medications with abuse
potential (Simoni-Wastila, Yang, 2006)
Older Adults
33http://www.ncoa.org/improve-health/center-for-healthy-aging/content-library/Prescription-
Medication-Misuse-and-Abuse-Webinar-12-12-11.ppt
34. Older Adult admissions for
substance abuse treatment nearly
triples, increasing from 13.7% in
1992 to 39.7% in 2008. CDC.
Older Adult admissions for substance abuse
treatment nearly tripled
What happened after ED visit?
52.3% were treated and released
37.5% were admitted to the hospital
34http://www.ncoa.org/improve-health/center-for-healthy-aging/content-library/Prescription-
Medication-Misuse-and-Abuse-Webinar-12-12-11.ppt
35. Drug-Related Emergency Department (ED) Visits
Resulting in Hospitalization among Adults Aged 50
or Older, by Type of Visit and Age Group: 2009
http://www.samhsa.gov/data/spotlight/Spot066DrugReaxOlderAdults2012.pdf
http://www.cdc.gov/MedicationSafety/Adult_AdverseDrugEvents.html
Older adults are at particular risk for experiencing adverse reactions to
medications. Compared with younger adults, they are more sensitive to
medications and more likely to take multiple medications because they
have more health problems that require treatment.
35
36. Unintentional Drug Overdose Deaths
by age group and sex, 2007
http://www.cdc.gov/HomeandRecreationalSafety/pdf/poison-issue-brief.pdf 36
41. Direct and indirect costs attributable to
illicit drug use are estimated in three
principal areas:
http://www.justice.gov/ndic/pubs44/44731/44731p.pdf
32%
6%62%
Crime
Health
Productivity
$61,376,694
$11,416,232
$120,303,004
$193 Billion
41
42. • Labor participation costs
• Specialty treatment costs for services
provided at the state level and the federal
level hospitalization costs
• Incarceration costs
• Premature mortality costs (nonhomicide &
homicide)
These subtotal $120,304,004.
Dollars in Thousands
42
43. Lost productivity due to premature mortality
remains a principal component of all costs that
drug use imposes on American society.
Age at Death for Males- Drug Related- 40-45 yrs
Age at Death for ALL Males 75-80 yrs
43
44. Crime cost includes three
components:
$56,373,254 criminal justice
system
$1,455,555 crime victim
$3,547,885 other crime
These subtotal $61,376,694
Dollars in Thousands
44
45. Health includes five components:
1. Specialty treatment costs ($3,723,338),
2. Hospital & emergency department costs for nonhomicide
cases ($5,684,248)
3. Hospital & emergency department costs for homicide cases
($12,938)
4. Insurance administration costs ($544)
5. Other health costs ($1,995,164).
These subtotal $11,416,232.
45
Dollars in Thousands
46. Drug courts can save states as much
$12,000 per client compared to other
criminal justice strategies, according to
the organization. CDC Accidental Overdoses
46www.cdc.gov/HomeandRecreationalSafety/pubs/RXReport_web-a.pdf
47. Saving Lives through Education &
Prevention
Legal Consequences:
2010 Legal Consequences of Prescription Drug
Misuse
Rx Drug Facts & Health Consequences of Misuse:
2010 Facts and Consequences of Nonmedical Use
of Prescription Drugs
47
48. 48
• The US is the only developed country in the world that
does not control RX drug prices.
• The US and New Zealand are the only countries that allow
drug makers to advertise to consumers.
• In medical schools the median # of hours for pain
education in the United States is 7 at VETINARIAN schools
the median required hours is 75.
• The pharmaceutical companies spent more on lobbying
between 1998 and 2004 than any other industry...
employing a legion of lobbyists.. more than two for each
member of Congress.
Overdoses involving prescription painkillers—a class of drugs that includes hydrocodone, methadone, oxycodone, and oxymorphone—are a public health epidemic. These drugs are widely misused and abused. One in 20 people in the United States, ages 12 and older, used prescription painkillers nonmedically (without a prescription or just for the "high" they cause) in 2010.
The highest drug overdose death rate was found in West Virginia, which was nearly 7 times that of the state with the lowest drug overdose death rate, South Dakota.
Of the 36,500 drug poisoning deaths in 2008, more than 40% (14,800) involved opioid analgesics
An 'immediate release' liquid or tablet that you take every 2 to 4 hours
* Age-adjusted rates per 100,000 population for OPR deaths, crude rates per 10,000 population for OPR abuse treatment admissions, and crude rates per 10,000 population for kilograms of OPR sold.Alternate Text: The figure above shows rates of opioid pain reliever (OPR) overdose death, OPR treatment admissions, and kilograms of OPR sold in the United States during 1999-2010. During 1999-2008, overdose death rates, sales, and substance abuse treatment admissions related to OPR all increased substantially.
The lag in death rate to opioid sales/state may be due to death rate #’s are 2008 and sales are 2010. TM.
more than twice as likely to use Marijuana (79.9 vs. 27.2%)
Older adults are at particular risk for experiencing adverse reactions to medications. Compared with younger adults, they are more sensitive to medications and more likely to take multiple medications because they have more health problems that require treatment.(*2) Older adults may also experience cognitive issues or memory problems that affect their ability to understand and follow medication instructions.(*3) To learn more about how to prevent adverse reactions to medications, older adults and their families can visit http://www.cdc.gov/MedicationSafety/Adult_AdverseDrugEvents.html.
By age, the distribution of MHSA hospitalizations differed substantially from the distribution of hospitalizations for all reasons and from the distribution of the U.S. population in 2008. Adults 18-64 years old accounted for a disproportionate share of all MHSA hospitalizations (83 percent) relative to their share of the total population (63 percent) and all hospitalizations (49 percent). While those 65 years and older were responsible for 35 percent of all stays and 13 percent of the U.S. population, they accounted for only 9 percent of MHSA stays. Children 1-17 years old accounted for 4 percent of all hospital stays and 7 percent of MHSA stays, compared to their population share of 23 percent. Children under 1 year accounted for 1 percent of the overall population, 12 percent of all hospital stays (mostly as newborns), and less than 0.1 percent of MHSA discharges (mostly for drug-related disorders).